The Effects of Normal Aging and ApoE Genotype on the Levels of CSF Biomarkers for Alzheimer's Disease

Overview

Journal Neurobiol Aging

Publisher Elsevier

Specialties Geriatrics
Neurology
Physiology

Date 2007 Oct 9

PMID 17920160

Citations 44

Authors

Lidia Glodzik-Sobanska

Elizabeth Pirraglia

Miroslaw Brys

Susan De Santi

Lisa Mosconi

Kenneth E Rich

Remigiusz Switalski

Leslie Saint Louis

Martin J Sadowski

Frank Martiniuk

Pankaj Mehta

Domenico Pratico

Raymond P Zinkowski

Kaj Blennow

Mony J de Leon

Affiliations

Soon will be listed here.

Abstract

While cerebrospinal fluid (CSF) biomarkers are of use in the prediction and diagnosis of Alzheimer's disease our understanding of the background effects of age and the ApoE genotype is limited. Seventy-eight community-based normal volunteers (mean age 60+/-10 years, range 36-86) were examined to determine the relationships between CSF measures of total tau (T-tau), hyperphosphorylated tau (P-tau 231), amyloid beta (Abeta42/Abeta40 ratio), and isoprostane (IP) with age and ApoE genotype. The results showed that age by epsilon4 genotype interactions were found for P-tau231 (beta=1.82; p<0.05) and IP (beta=1.6; p<0.05). T-tau CSF concentration increased with age. The increasing CSF concentrations of P-tau and IP in epsilon4 carriers suggest that early tauopathy and oxidative stress may be related to the increased risk for AD. The data also suggest that T-tau changes are more age dependent than Abeta changes. The evidence that P-tau231 and IP are the earliest markers for the neuronal damage related to AD awaits longitudinal study.

Citing Articles

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model.

Carling G, Fan L, Foxe N, Norman K, Wong M, Zhu D Neuron. 2024; 112(23):3877-3896.e8.

PMID: 39353433 PMC: 11624100. DOI: 10.1016/j.neuron.2024.09.006.

Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.

Zimmermann M, Fandrich M, Jakobi M, Roben B, Wurster I, Lerche S J Parkinsons Dis. 2024; 14(7):1405-1416.

PMID: 39240648 PMC: 11492048. DOI: 10.3233/JPD-240115.

Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease.

Perluigi M, Di Domenico F, Butterfield D Physiol Rev. 2023; 104(1):103-197.

PMID: 37843394 PMC: 11281823. DOI: 10.1152/physrev.00030.2022.

Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease.

Mok T, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T Brain. 2023; 146(6):2570-2583.

PMID: 36975162 PMC: 10232278. DOI: 10.1093/brain/awad101.

APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression.

Dincer A, Chen C, McKay N, Koenig L, McCullough A, Flores S Sci Transl Med. 2022; 14(671):eabl7646.

PMID: 36383681 PMC: 9912474. DOI: 10.1126/scitranslmed.abl7646.

References

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

Arai H, Morikawa Y, Higuchi M, Matsui T, Clark C, Miura M . Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997; 236(2):262-4. DOI: 10.1006/bbrc.1997.6908. View

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R . Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2007; 30(5):682-90. PMC: 2774781. DOI: 10.1016/j.neurobiolaging.2007.08.010. View

Zhu X, Raina A, Lee H, Chao M, Nunomura A, Tabaton M . Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal. 2003; 5(5):571-6. DOI: 10.1089/152308603770310220. View

Pratico D, Clark C, Liun F, Rokach J, Trojanowski J . Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002; 59(6):972-6. DOI: 10.1001/archneur.59.6.972. View

Ohm T, Scharnagl H, Marz W, Bohl J . Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. 1999; 98(3):273-80. DOI: 10.1007/s004010051080. View

Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H . Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem. 2007; 101(4):1053-9. DOI: 10.1111/j.1471-4159.2006.04404.x. View

Burkhard P, Fournier R, Mermillod B, Krause K, Bouras C, Irminger I . Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin Chem Lab Med. 2004; 42(4):396-407. DOI: 10.1515/CCLM.2004.071. View

Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C . Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett. 1997; 225(3):213-5. DOI: 10.1016/s0304-3940(97)00228-0. View

10.

Mitchell A, Brindle N . CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?. Int J Geriatr Psychiatry. 2003; 18(5):407-11. DOI: 10.1002/gps.845. View

11.

Blennow K, Vanmechelen E . CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull. 2003; 61(3):235-42. DOI: 10.1016/s0361-9230(03)00086-8. View

12.

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

13.

Blennow K . CSF biomarkers for mild cognitive impairment. J Intern Med. 2004; 256(3):224-34. DOI: 10.1111/j.1365-2796.2004.01368.x. View

14.

Pratico D, Clark C, Lee V, Trojanowski J, Rokach J, FitzGerald G . Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000; 48(5):809-12. View

15.

Greenow K, Pearce N, Ramji D . The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl). 2005; 83(5):329-42. DOI: 10.1007/s00109-004-0631-3. View

16.

Uylings H, De Brabander J . Neuronal changes in normal human aging and Alzheimer's disease. Brain Cogn. 2002; 49(3):268-76. DOI: 10.1006/brcg.2001.1500. View

17.

De Caterina R, Cipollone F, Filardo F, Zimarino M, Bernini W, Lazzerini G . Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002; 106(20):2543-9. DOI: 10.1161/01.cir.0000038500.43292.d7. View

18.

CATALANO F . A preliminary report on a new memory scale. Percept Mot Skills. 1968; 27(1):277-8. DOI: 10.2466/pms.1968.27.1.277. View

19.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

20.

Galasko D, Chang L, Motter R, Clark C, Kaye J, Knopman D . High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998; 55(7):937-45. DOI: 10.1001/archneur.55.7.937. View